Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

This article was originally published on Nasdaq

Investors might want to bet on Rapt Therapeutics (RAPT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates — one of the most powerful forces impacting stock prices.

Responses